CAMBRIDGE, Mass., and BEIJING, China, Feb. 07, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day in New York, NY. The presentation is scheduled for 2:30 p.m. EST on Thursday, February 14, 2019.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact
Craig West
+1 857-302-5189
[email protected]
Media Contact
Liza Heapes
+1 857-302-5663
[email protected]
________________________________
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.
